Novartis (NVS) Competitors

13.1% of Novartis shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novartis presently has a consensus price target of $141.20, indicating a potential downside of 11.23%. Johnson & Johnson has a consensus price target of $268.22, indicating a potential downside of 0.91%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Novartis.

Novartis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Novartis has a net margin of 23.29% compared to Johnson & Johnson's net margin of 21.48%. Novartis' return on equity of 38.56% beat Johnson & Johnson's return on equity.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Novartis pays out 46.5% of its earnings in the form of a dividend. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Johnson & Johnson had 52 more articles in the media than Novartis. MarketBeat recorded 60 mentions for Johnson & Johnson and 8 mentions for Novartis. Johnson & Johnson's average media sentiment score of 1.04 beat Novartis' score of 0.69 indicating that Johnson & Johnson is being referred to more favorably in the news media.

13.1% of Novartis shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Novartis has a net margin of 23.29% compared to Merck & Co., Inc.'s net margin of 4.77%. Novartis' return on equity of 38.56% beat Merck & Co., Inc.'s return on equity.

In the previous week, Merck & Co., Inc. had 89 more articles in the media than Novartis. MarketBeat recorded 97 mentions for Merck & Co., Inc. and 8 mentions for Novartis. Novartis' average media sentiment score of 0.69 beat Merck & Co., Inc.'s score of 0.59 indicating that Novartis is being referred to more favorably in the media.

Novartis currently has a consensus target price of $141.20, suggesting a potential downside of 11.23%. Merck & Co., Inc. has a consensus target price of $144.10, suggesting a potential downside of 5.46%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Novartis.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.2%. Novartis pays out 46.5% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has increased its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Merck & Co., Inc. has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Astrazeneca currently has a consensus price target of $211.00, suggesting a potential upside of 27.11%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 11.23%. Given Astrazeneca's stronger consensus rating and higher possible upside, research analysts plainly believe Astrazeneca is more favorable than Novartis.

Novartis has lower revenue, but higher earnings than Astrazeneca. Novartis is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Novartis has a net margin of 23.29% compared to Astrazeneca's net margin of 17.02%. Novartis' return on equity of 38.56% beat Astrazeneca's return on equity.

In the previous week, Astrazeneca had 4 more articles in the media than Novartis. MarketBeat recorded 12 mentions for Astrazeneca and 8 mentions for Novartis. Novartis' average media sentiment score of 0.69 beat Astrazeneca's score of 0.59 indicating that Novartis is being referred to more favorably in the news media.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 7 more articles in the media than Novartis. MarketBeat recorded 15 mentions for Novo Nordisk A/S and 8 mentions for Novartis. Novartis' average media sentiment score of 0.69 beat Novo Nordisk A/S's score of 0.57 indicating that Novartis is being referred to more favorably in the news media.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 1.8%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 1.9%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Novo Nordisk A/S has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Novo Nordisk A/S presently has a consensus price target of $64.94, indicating a potential upside of 38.73%. Novartis has a consensus price target of $141.20, indicating a potential downside of 11.23%. Given Novo Nordisk A/S's higher probable upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity.